

REVIEW



Assessing immune aging in HIV-infected patients

Victor Appay^{a,b} and Delphine Sauce^{a,b}

^aSorbonne Universités, UPMC Univ Paris 06, Center d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; ^bINSERM U1135, CIMI-Paris, Paris, France

ABSTRACT

Many of the alterations that affect innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations define the immunological age of individuals and are likely to participate to the decline of immune competence with HIV disease progression. It is therefore important to characterize these changes, which point toward the accumulation of highly differentiated immunocompetent cells, associated with overall telomere length shortening, as well as understanding their etiology, especially related to the impact of chronic immune activation. Particular attention should be given to the exhaustion of primary immune resources, including haematopoietic progenitors and naïve cells, which holds the key for effective hematopoiesis and immune response induction, respectively. The alteration of these compartments during HIV infection certainly represents the foundation of the immune parallel with aging.

ARTICLE HISTORY

Received 18 April 2016
Accepted 20 May 2016

KEYWORDS

aging; hematopoiesis; HIV; immunosenescence; lymphocytes; naïve cells

Introduction

More than 30 y of research have taught us that the pathogenesis of HIV infection is highly complex. The infection of CD4⁺ T cells, the primary target of the virus, represents the most fundamental feature of HIV pathogenesis. The depletion of these cells (in particular in mucosal lymphoid tissues like the gastrointestinal tract), necessary to maintain immune competence, eventually coincides with the onset of AIDS. The increased expression of a series of co-inhibitory receptors, nowadays referred to as immune check points, on chronically activated effector T and B cells play also an important role in dampening the functional efficacy of the anti-HIV response. However, we have come to realize that many other compartments of the immune system are actually affected during the course of HIV infection. Many of these immune alterations are reminiscent of the process of immune aging, that usually occurs with advanced age, and likely participates to the decline of immune competence in HIV-infected patients. We review below the multiple aging like alterations that have been reported in the different cellular compartments of the immune system, and how assessing these parameters gives us clues on the immunological age of patients infected by HIV.

Shortening of telomere length

Telomeres, which are special structures of tandem repeats at the end of chromosomes, are essential for chromosomal

stability. In humans, telomeric DNA consists of TTAGGG repeat tracts of about 10 kb in length. In somatic cells, telomere length is shortened with each cell division due to the inability of DNA polymerase to replicate the extreme 5' end of the lagging strand of DNA. Telomere length shortening is the classical marker of cellular senescence, and therefore commonly used as an indicator of the biological age of individuals.

In a longitudinal follow-up over 3–9 years, telomere length of total PBMCs from HIV-infected individuals was shown to shorten at an accelerated rate compared to age-matched seronegative controls.¹ In HIV-infected patients, the mean telomeric restriction fragment (TRF) length loss was greater in progressors (175 + 105 bp/year) than in asymptomatic individuals (114 + 100 bp/year), and both were significantly increased compared with healthy controls (4.7 + 71 bp/year). Telomere shortening was consistently observed in the CD8⁺ T cells, with only minimal or no telomere shortening in the CD4⁺ T cells.¹ TRF shortening in the CD8⁺ T cell compartment accounted mainly for the expansion of cells lacking the expression of the co-receptor CD28, associated with short telomeres.² In fact, the telomere length of the CD8⁺ CD28⁻ T cells were the same size as those of uninfected centenarian lymphocytes. B cell telomere shortening was also documented in HIV-infected patients,³ consistent with the well-documented hyperactivation observed during HIV infection. Changes in mean TRF length were also examined in HIV-infected patients

initiating anti-retroviral therapy (ART). Increases in mean T cell TRF lengths were observed in most patients following therapy. However, the contribution of individual T cell subsets was complex. An elongation of CD8⁺ T cell TRF was nearly uniformly observed, while changes in mean TRF length in CD4⁺ T cells were heterogeneous, despite potent suppression of viral replication.⁴

Faster PBMC or T cell telomere erosion in HIV-infected patients is suggestive of accelerated immunological aging with HIV infection. However, a caveat in these studies is that telomere length was usually measured in total PBMC or in total T cell subsets (i.e. CD4 or CD8). Telomerase activity and telomere length indeed vary in distinct cell subsets according to the stage of differentiation (e.g. naïve, effector and memory cells). Since the distribution of such cell subsets is known to change during the course of HIV infection, the observation of overall TRF shortening may therefore reflect these cell distribution changes.

Aging of the adaptive immune compartment

Accumulation of CD28⁻/CD57⁺ CD8⁺ T cells

Following their maturation and production in the thymus, both CD8⁺ and CD4⁺ T cells can be divided into multiple subsets of naïve and effector/memory cells, which are identified according to the expression of a variety of cell surface receptors (e.g., CD45RA, CCR7, CD27, CD28, CD57, CD95) and present distinct functions and properties.⁵

The first immune parallel drawn between aging and HIV infection has been the accumulation of CD8⁺ T lymphocytes lacking expression of the co-receptor CD28.^{2,6} These cells represent a population of differentiated memory T cells, which are characterized by a reduced capacity to produce IL-2 and to proliferate, short telomere lengths, as well as altered metabolism.^{7,8} In this population, CD57⁺ cells, considered as end-stage senescent cells (with the shortest telomeres) also accumulate.^{9,10} A similar process occurs for CD4⁺ T cells, although the raise of CD28⁻ cells is less obvious in this compartment compared to CD8⁺ T cells. Highly differentiated T cells accumulate as a consequence of chronic cellular activation, often associated with chronic replication of HIV, as well as other persistent viruses, in particular cytomegalovirus (CMV), co-infecting patients. Immune activation indeed drives the proliferation and differentiation of virus specific T lymphocytes, that eventually loose expression of CD28, and display CD57.⁹⁻¹³ The accumulation of CD28⁻/CD57⁺ T cells is commonly used as a marker of “immunosenescence” in HIV-infected patients.

Interestingly, this marker, together with a marker of T cell activation (HLA-DR expression) was recently used

to generate a score of immune activation and senescence. This immune score was correlated with the clinical state of HIV-infected patients and was significantly associated with the raise of non-AIDS related multi-morbidities (e.g. kidney disease, diabetes, dyslipidemia, cardiovascular events, hypertension, degenerative central nervous system disorders, and cancer) in treated patients younger than 60 y.¹⁴ Moreover, increased frequencies of CD28⁻/CD57⁺ CD8⁺ T cells have been associated with the presence of Kaposi's sarcoma among successfully treated patients.¹⁵ However, the frequency of these cells does not decrease in HIV-infected patients upon initiation of anti-retroviral therapy (ART), even with good CD4⁺ T cell recovery.¹⁶ In addition, ART naïve HIV controllers can display high levels of these cells.¹⁶ This indicates that the accumulation of CD28⁻/CD57⁺ CD8⁺ T cells is not necessarily a strict marker of HIV disease progression and decline of immune competence. Of note, the accumulation of CD28⁻/CD57⁺ CD8⁺ T cells is independent and unrelated to the increased expression of co-inhibitory receptors (such as PD-1) on CD8⁺ T cells, that is not a characteristic of old age, and not a marker of immunological aging.¹⁷

Quantitative and qualitative alterations of naïve T cells

Another important immune parallel between aging and HIV infection is the reduction in CD4⁺ and CD8⁺ naïve T cell frequencies. As it is observed with advanced age, the capacity of the thymus to produce new T cells, or thymic output, decreases significantly during the course of HIV infection,¹⁸⁻²⁰ which may in part explain the decline of naïve T cells. In a human model of premature immune aging (i.e., thymectomized young adults), decreased naïve T cell frequency was indeed shown to be the consequence of inadequate T cell renewal capacity due to reduced thymic output, together with their consumption upon chronic activation due to a persistent virus infection.^{21,22} Interestingly, perinatally HIV-infected subjects displayed preserved naïve T cell counts associated with high recent thymic immigrant levels even 15 y after infection, highlighting the role of persistent thymic activity to compensate for the loss and consumption of this compartment.²³ Moreover, HIV-2 infected patients, who usually control the virus and do not progress toward AIDS, maintain a robust thymic out and good naïve T cell counts.²⁴ In HIV-infected patients, the pool of naïve T cells is usually partially restored upon initiation of ART, except in the case of immunological failure, when patients fail to reconstitute their immune system despite the treatment.²⁵ Overall, the frequency of naïve T cells represents a good marker of immunological age in humans, and its

progressive decrease in HIV-infected adults is usually directly associated with HIV disease progression.^{16,26} Of note, as patients progress toward the disease, the decline in naïve T cell counts is correlated with evidence of homeostatic proliferation (i.e. Ki67 expression), likely as a mean to maintain adequate levels of these cells, similarly as with advanced age.²⁷

In addition to these quantitative alterations, the naïve T cell compartment is also characterized by functionally impairments during HIV infection. Naïve CD8⁺ T cells from HIV-infected patients present signaling defects and a lower capacity to be activated upon T cell receptor stimulation.²⁸ Although its exact cause remained to be determined, this impairment is similar to observations in elderly subjects.²⁹ Since the induction of *de novo* adaptive immune responses relies on the activation of naïve T cells specific for a given neoantigen, quantitative and qualitative alterations of this compartment are likely to impact on the ability of HIV-infected patients to mount new effective immune responses. Ineffective capacity to mount immunity against emerging HIV mutants and therefore to control new viral variants will certainly contribute to the onset immunodeficiency and HIV disease. Likewise, vaccine efficacy against HIV or other pathogens is also at stake. In fact, HIV-infected patients, like the uninfected elderly, show poorer responses to influenza vaccination.^{30,31}

Unbalanced B-cell memory subset distribution

In healthy humans, B cells develop and convert into transitional cells in the bone marrow, then migrate into the periphery, where they finally mature in naïve B cells. After contacting the antigen, naïve B cells activate and differentiate into plasma cells, able to secrete specific antibodies. When immune responses end, only a minority of specific B cells survives and constitutes the pool of resting memory B cells.³² These B cell subpopulations are identified in most studies by different expression of IgD, IgM, CD10, CD19, CD27, CD10, CD24, CD38 and CD21.³³

The number of circulating B cells significantly decreases with age and the diversity of B cell repertoire is reduced.³⁴ Furthermore, the relative frequencies of the different B cell subsets are altered: it has been shown that naïve B cells (IgD⁺ CD27⁻) and switched memory B cells (IgD⁻ CD27⁺), predicting optimal antibody responses,¹² decrease with age.³⁵ Conversely, the antigen-experienced late/exhausted memory B cells (IgD⁻ CD27⁻) increase with age.³⁶

Like in older individuals, B-cell lymphopenia is described in HIV-infected individuals as well as a reduced frequency of resting memory B cells (IgD⁻ CD27⁺); this reduction was paralleled by increased levels

of exhausted B cells (CD20⁺, CD21^{low}, CD27⁻, referred in aging as IgD⁻ CD27⁻), which correlated with viremia and a reduced immunosurveillance.³⁷⁻⁴¹ Another common feature of B cell alteration is their hyperactivation, characterized by an hypergammaglobulinaemia⁴²⁻⁴⁵; and an increased expression of activation markers, including CD70, CD71, CD80 and CD86. Potent antiretroviral therapy normalizes B cell counts and the relative percentages of the main B lymphocyte subsets⁴⁶ as well as gammaglobulinaemia.⁴⁷ Moreover, ART can normalize CD70, CD71, CD80, and CD86 expression.⁴⁸ However, even potent treatments are not able to fully revert the loss of memory B cells and their function during chronic infection at the level observed in healthy individuals.^{38,46,49-51}

Aging of the innate immune compartment

Preferential expansion of mature NK cells

Based on surface CD56 density, NK cells are categorized into 3 distinct subsets: the cytokine producing CD56⁺⁺CD16⁻ subset, the cytotoxic CD56⁺CD16⁺ subset, and a minor CD56⁻CD16⁺ NK cell subset with poor antiviral activity. With aging or HIV infection, the distribution of NK cell subsets and their functions are altered.⁵² Gradual loss of the CD56⁺⁺ NK cell subset is observed in both contexts, probably due to limited production of its precursors, while an expansion of dysfunctional CD56⁻CD16⁺ NK cells is described.^{53,54} The expansion of this CD56⁻ CD16⁺ NK cell population has been suggested to be a mechanism to compensate for the loss of CD56⁺ NK cells in order to maintain overall NK cell homeostasis in HIV-infected individuals.⁵² Moreover, the rapid CD56⁻ NK cell expansion has also been argued as a consequence of high viremia, since both parameters strongly correlate with each other but not in virally suppressed LTNP. ⁵⁵

Concerning the predominant CD56⁺ NK cells, their properties are also modified with age or during the course of HIV infection. Indeed, highly differentiated mature CD57⁺CD56⁺CD16⁺ NK cells accumulated with aging (in particular in CMV seropositive donors).⁵⁶⁻⁵⁸ In HIV patients, it is their functionality which is modified: these cells display a decreased ability to kill virus-infected target cells and to interact with other cellular components of the adaptive immune system.^{59,60} During chronic HIV infection, there is an impairment of NK cell cytotoxicity and cytokine secretion as well as a reduced capacity to respond to IFN- α and to produce high amounts of IFN- γ and TNF α along with low amounts of perforin.⁶¹ Similarly, NK cell repertoire diversity, that might influence immune surveillance, is differentially impacted during aging and HIV infection.⁶²⁻⁶⁵ However, a direct comparison between

HIV infected patients and elderly individuals is difficult to establish since their respective CD56⁺ cell subsets have been characterized according to different criteria (phenotype, function or repertoire). Further studies of the various attributes of CD56⁺ NK cells are needed to understand this parallel between HIV infection and aging.

ART does not significantly influence the recovery of NK cell function, as IFN- γ production⁶⁶ and repertoire (e.g., NKp46, NKp30, NKp44 and KIRs) expression may be persistently impaired even after successful therapy.^{65,67} NK cells from treated HIV-infected patients have reduced expression of key signaling proteins that are required for antibody-dependent cellular cytotoxicity; however, the factors causing this phenomenon are unknown.⁶⁸ Moreover, virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation.⁶⁹ It remains to elucidate if NK cells from elderly people exhibit a similar activation pattern.

Over-representation of CD16⁺ monocytes

Monocytes play an important role in defense against microbial pathogens and inflammation. Three main subpopulations of monocytes are described: classical (CD14⁺⁺ CD16⁻) that expresses CD62L, CCR2 and low levels of CX3CR1, intermediate (CD14⁺⁺CD16⁺) that lacks CD62L or CCR2 but expresses CX3CR1 and secretes high level of TNF- α in response to Toll-like receptors (pro-inflammatory monocytes), and non-classical (CD14⁺CD16⁺⁺), CCR2low CX3CR1high.

Several phenotypic and functional changes observed in monocytes from HIV seropositive patients are similar to those observed in elderly uninfected individuals. Indeed, monocytes from HIV-infected patients or old subjects possess characteristics of activated cells, such as spontaneous production of proinflammatory cytokines, expression of CD38, CD69, CD11b, HLA-DR, and CD86, and decreased CD62L (reviewed in⁷⁰). In HIV-infected patients, CD69 and HLA-DR expression correlates well with plasma levels of lipopolysaccharide, which is an indicator of microbial translocation.⁷¹ Despite relatively few changes in the absolute numbers of monocytes, the distribution of the different subsets is changed, characterized by a marked reduction in classical monocytes and an increased frequency of intermediate and non-classical monocytes in older or HIV infected patients.⁷²⁻⁷⁴ These CD16⁺ monocytes are increased during the infection and are correlated with viremia, T cell activation, and with plasma levels of IL-6. They are expanded in patients who do not take therapy or discontinue treatment. On the contrary, in patients under effective ART, the expression of CD16 is similar to that of uninfected controls.⁷⁵ Moreover, plasma levels of soluble

CD163 and CXCL10, both markers associated with monocyte activation, also increase with both age and HIV.^{72,76} These biomarkers of monocyte activation are only partially normalized upon ART mediated viral suppression,⁷⁷ suggesting that these changes may contribute to the increased risk of inflammatory age-related diseases in treated HIV-positive individuals.⁷⁶

Biased frequency of plasmacytoid DC

Two major subsets of circulating DCs have been described, that are, myeloid DC (mDC) and plasmacytoid DC (pDC), which differ in ontogeny, phenotype, and function. pDCs (BDCA-2⁺ BDCA-4⁺ CD123⁺) are involved in antiviral immunity and predominantly produce Type I IFNs. Conversely, mDCs (BDCA-1⁺ CD11c⁺) sense both bacterial and viral pattern motifs through a broader range of TLRs and are involved in the induction of Th1- and Th2-type responses. Both subsets exhibit a functional plasticity in directing T-cell responses.⁷⁸ Alterations in DC numbers, phenotype, and function exist in the elderly, where reduced pDC numbers and increased expression of CD40 and CD86 have also been described.⁷⁹⁻⁸¹ The DC changes described during the course of HIV infection are reminiscent of the situation observed in elderly subjects⁸²⁻⁸⁴: in particular peripheral pDC numbers are decreased.⁸⁵ This loss correlated with high viral load and the occurrence of opportunistic infections.^{82,84,86} Costimulatory or activation markers (such as CD40, CD80, CD83, CD86, CD38, HLA-DR, and PD-L1) of both mDC and pDC have also been investigated in HIV-infected subjects and revealed an activated phenotype.⁸⁷ Primary dendritic cell function in aging generally shows decreased TLR-dependent cytokine production in both mDC and pDC populations. Notably, basal cytokine production was markedly elevated in mDCs and pDCs from older, but not young subjects, reflecting the heightened pro-inflammatory environment of aging (another similarity to HIV). So far, studies in HIV patients have not reached a consensus with regards to this point.^{88,89} Further efforts should address if DCs from HIV patients show altered functional patterns as in the elderly.

Exhausted hematopoiesis

The alteration of many major compartments of innate and adaptive immune cells during the course of HIV infection points toward a possible defect of hematopoiesis (i.e., the generation of immunocompetent cells). A number of studies have indeed shown that hematopoietic stem cells from HIV-infected patient bone marrows present functional alterations, suggesting impaired hematopoiesis in HIV infection.⁹⁰⁻⁹³ Compared to healthy donors or HIV-infected

non-progressors, patients progressing toward AIDS, like uninfected elderly people, have decreased numbers of circulating hematopoietic progenitor cells (HPCs), and their remaining CD34⁺ cells present functional alterations (e.g. reduced clonogenic potential).²⁵ CD34⁺ HPCs from these individuals display a preferential reduction in cells with lymphoid precursor capacity, along with an impaired capacity to generate T lymphocytes in *in vitro* culture assays.⁹⁴⁻⁹⁶ Deterioration of the hematopoietic system with advanced age is certainly thought to be a key issue in the overall decline of immune competence of the old person, and is a likely cause of the accelerated immune aging profile in HIV-infected individuals. In the latter, ART restores partially the HPC compartment and a normal hematopoiesis, associated with the reconstitution of all immunocompetent cell pools.²⁵ A recent study reveals that, upon ART initiation, CD4⁺ T cell recovery was correlated with the ability of HPCs to proliferate, showing the importance of bone marrow derived HPCs to reconstitute the immune system during HIV infection.⁹⁷ Of note, in treated patients presenting immunological failure despite effective suppression of viral replication, ART failed to re-establish hematopoietic resources, which seemed fully exhausted.²⁵

Deterioration of the hematopoietic system with advanced age is thought to result from life-long mobilization of resources and intrinsic cellular impairments (of both HPCs and stromal cells). The fine mechanisms underlying the exhaustion of hematopoiesis during untreated HIV infection still need to be addressed. Altered lymphopoiesis in HIV-infected patients probably results from the combination of multiple factors. Evidence for the infection by HIV and apoptosis of hematopoietic progenitors has been reported.⁹⁸ However, HIV infection mediated depletion of CD34⁺ cells remains debated.⁹⁹⁻¹⁰² Nef was shown to have inhibitory effects on HPC multipotent potential.^{103,104} HIV may also infect and deplete bone marrow stromal auxiliary cells, which has been suggested as a potential cause of disrupted hematopoiesis.¹⁰⁵ In addition, elevated systemic immune activation may have a major effect on HPC activity and hematopoiesis. The lack of correlation between viral replication and CD34⁺ cell levels suggests that a direct effect of the virus on hematopoiesis disruption may only be secondary, in comparison with the effect of immune activation.²⁵ The association between plasma sCD14 levels and CD34⁺ cell counts in untreated patients suggests that high levels of microbial products such as lipopolysaccharide (LPS; associated with bacterial translocation), or IFN- α (associated with activation of plasmacytoid dendritic cells), which result in monocyte activation and are both associated with disease progression in HIV or SIV infection^{106,107} might participate in disrupting lymphopoiesis.

Concluding remarks

Among the constellation of immunological alterations observed during the course of HIV infection, many highlight a clear immune parallel between HIV disease progression and aging. HIV-infected patients can display innate and adaptive immunosenescence like attributes, sometimes decades before uninfected people. Elevated chronic immune activation is the most likely drivers of this phenomenon, although the precise mechanisms (e.g., systemic inflammation related damages or viral antigen driven consumption of immunocompetent cells) still need to be determined in details. The majority of these immune aging alterations points toward the accumulation of more mature and differentiated innate and adaptive immune cells. The increased proportion of these cells accounts, to a great extent, for the reduced telomere length observed in PBMCs of HIV-infected patients. However, comprehensive analyses of telomere length and telomerase activity in the different subsets of T, B, NK cells, according to their stage of differentiation, may be required. In particular, it will be important to assess telomere length directly in primary immune cell compartments, such as HPCs and naïve cells, which embody the source of hematopoiesis and immune response induction respectively. The alteration of these compartments during HIV infection certainly represents the foundation of the immune parallel with aging, and the decline of the immune system fitness. Their fine characterization is necessary to draw a complete picture of the immunological age according to HIV disease progression and chronological age, and of the remaining hematopoietic potential of HIV-infected patients.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Funding

VA and DS receive financial support from INSERM, FRM, ANR, ANRS, and Sidaction.

References

- [1] Wolthers KC, Bea G, Wisman A, Otto SA, de Roda Husman AM, Schaft N, de Wolf F, Goudsmit J, Coutinho RA, van der Zee AG, et al. T cell telomere length in HIV-1 infection: no evidence for increased CD4⁺ T cell turnover. *Science* 1996; 274:1543-7; PMID:8929418; <https://doi.org/10.1126/science.274.5292.1543>
- [2] Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, Wang L, Harley CB, Villeponteau B, West MD, Giorgi JV. Shortened telomeres in the expanded CD28-CD8+

- cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. *AIDS* 1996; 10:F17-22; PMID:8828735; <https://doi.org/10.1097/00002030-199607000-00001>
- [3] Pommier JP, Gauthier L, Livartowski J, Galanaud P, Boue F, Dulioust A, Marcé D, Ducray C, Sabatier L, Lebeau J, et al. Immunosenescence in HIV pathogenesis. *Virology* 1997; 231:148-54; PMID:9143314; <https://doi.org/10.1006/viro.1997.8512>
- [4] Kaushal S, Landay AL, Lederman MM, Connick E, Spritzler J, Kuritzkes DR, Kessler H, Levine BL, St Louis DC, June CH. Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. *Clin Immunol* 1999; 92:14-24; PMID:10413649; <https://doi.org/10.1006/clim.1999.4726>
- [5] Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. *Cytometry A* 2008; 73:975-83; PMID:18785267; <https://doi.org/10.1002/cyto.a.20643>
- [6] Weng NP, Akbar AN, Goronzy J. CD28(-) T cells: their role in the age-associated decline of immune function. *Trends Immunol* 2009; 30:306-12; PMID:19540809; <https://doi.org/10.1016/j.it.2009.03.013>
- [7] Henson SM, Lanna A, Riddell NE, Franzese O, Macaulay R, Griffiths SJ, Puleston DJ, Watson AS, Simon AK, Tooze SA, et al. p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8(+) T cells. *J Clin Invest* 2014; 124:4004-16; PMID:25083993; <https://doi.org/10.1172/JCI75051>
- [8] Lanna A, Henson SM, Escors D, Akbar AN. The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. *Nat Immunol* 2014; 15:965-72; PMID:25151490; <https://doi.org/10.1038/ni.2981>
- [9] Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. *Blood* 2003; 101:2711-20; PMID:12433688; <https://doi.org/10.1182/blood-2002-07-2103>
- [10] Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A, Easterbrook P, et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. *PLoS Biol* 2004; 2:E20; PMID:14966528; <https://doi.org/10.1371/journal.pbio.0020020>
- [11] Gamadia LE, van Leeuwen EM, Remmerswaal EB, Yong SL, Surachno S, Wertheim-van Dillen PM, Ten Berge IJ, Van Lier RA. The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. *J Immunol* 2004; 172:6107-14; PMID:15128796; <https://doi.org/10.4049/jimmunol.172.10.6107>
- [12] Frasca D, Diaz A, Romero M, Phillips M, Mendez NV, Landin AM, Blomberg BB. Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. *Int Immunol* 2012; 24:175-82; PMID:22281510; <https://doi.org/10.1093/intimm/dxr123>
- [13] Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, et al. Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. *J Infect Dis* 2013; 207:622-7; PMID:23204178; <https://doi.org/10.1093/infdis/jis732>
- [14] Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, Moreau JF, Dauchy FA, Cazanave C, Vandenhende MA, et al. Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. *AIDS* 2015; 29:2099-108; PMID:26544576; <https://doi.org/10.1097/QAD.0000000000000807>
- [15] Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG, Deeks SG, et al. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. *AIDS* 2013; 27:1735-42; PMID:23435301; <https://doi.org/10.1097/QAD.0b013e3283601144>
- [16] Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, Keller M, Grubeck-Loebenstien B, Simon A, Lambotte O, et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. *AIDS* 2011; 25:1813-22; PMID:21412126; <https://doi.org/10.1097/QAD.0b013e32834640e6>
- [17] Petrovas C, Chaon B, Ambrozak DR, Price DA, Melenhorst JJ, Hill BJ, Geldmacher C, Casazza JP, Chattopadhyay PK, Roederer M, et al. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. *J Immunol* 2009; 183:1120-32; PMID:19564339; <https://doi.org/10.4049/jimmunol.0900182>
- [18] Dion ML, Poulin JF, Bordi R, Sylvestre M, Corsini R, Kettaf N, Dalloul A, Boulassel MR, Debré P, Routy JP, et al. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. *Immunity* 2004; 21:757-68; PMID:15589165; <https://doi.org/10.1016/j.immuni.2004.10.013>
- [19] Fabre-Mersseman V, Dutrieux J, Louise A, Rozlan S, Lamine A, Parker R, Rancez M, Nunes-Cabaço H, Sousa AE, Lambotte O, et al. CD4(+) recent thymic emigrants are infected by HIV in vivo, implication for pathogenesis. *AIDS* 2011; 25:1153-62; PMID:21505308; <https://doi.org/10.1097/QAD.0b013e3283471e89>
- [20] Lelievre JD, Melica G, Itti E, Lacabaratz C, Rozlan S, Wiedemann A, Cheynier R, Meignan M, Thiebaut R, Levy Y. Initiation of c-ART in HIV-1 infected patients is associated with a decrease of the metabolic activity of the thymus evaluated using FDG-PET/computed tomography. *J Acquir Immune Defic Syndr* 2012; 61:56-63; PMID:22706292; <https://doi.org/10.1097/QAI.0b013e3182615b62>
- [21] Sauce D, Larsen M, Fastenackels S, Duperrier A, Keller M, Grubeck-Loebenstien B, Ferrand C, Debré P, Sidi D, Appay V. Evidence of premature immune aging in patients thymectomized during early childhood. *J Clin Invest* 2009; 119:3070-8; PMID:19770514; <https://doi.org/10.1172/JCI39269>
- [22] Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, et al. Changes in thymic function with age and

- during the treatment of HIV infection. *Nature* 1998; 396:690-5; PMID:9872319; <https://doi.org/10.1038/25374>
- [23] Blanche S, Scott-Algara D, Le Chenadec J, Didier C, Montange T, Avettand-Fenoel V, Rouzioux C, Méléard A, Viard JP, Dollfus C, et al. Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study. *Clin Infect Dis* 2014; 58:573-87; PMID:24253249; <https://doi.org/10.1093/cid/cit729>
- [24] Gautier D, Beq S, Cortesao CS, Sousa AE, Cheynier R. Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T cells during chronic human immunodeficiency virus type 2 infection. *J Virol* 2007; 81:12685-8; PMID:17804512; <https://doi.org/10.1128/JVI.01131-07>
- [25] Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, Guihot A, Boufassa F, Zaunders J, Iguertsira M, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. *Blood* 2011; 117:5142-51; PMID:21436070; <https://doi.org/10.1182/blood-2011-01-331306>
- [26] Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. *J Clin Invest* 1995; 95:2061-6; PMID:7738173; <https://doi.org/10.1172/JCI117892>
- [27] Sauce D, Larsen M, Fastenackels S, Roux A, Gorochov G, Katlama C, Sidi D, Sibony-Prat J, Appay V. Lymphopenia-driven homeostatic regulation of naive T cells in elderly and thymectomized young adults. *J Immunol* 2012; 189:5541-8; PMID:23136199; <https://doi.org/10.4049/jimmunol.1201235>
- [28] Favre D, Stoddart CA, Emu B, Hoh R, Martin JN, Hecht FM, Deeks SG, McCune JM. HIV disease progression correlates with the generation of dysfunctional naive CD8 (low) T cells. *Blood* 2011; 117:2189-99; PMID:21200021; <https://doi.org/10.1182/blood-2010-06-288035>
- [29] Briceno O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, Miquel T, Gostick E, Papagno L, Stiasny K, et al. Reduced naive CD8(+) T-cell priming efficacy in elderly adults. *Aging Cell* 2015; 15:14-21; PMID:26472076; <https://doi.org/10.1111/acer.12384>
- [30] George VK, Pallikkuth S, Parmigiani A, Alcaide M, Fischl M, Arheart KL, Pahwa S. HIV infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine. *J Infect Dis* 2015; 211:1959-68; PMID:25556252; <https://doi.org/10.1093/infdis/jiu840>
- [31] Parmigiani A, Alcaide ML, Freguja R, Pallikkuth S, Frasca D, Fischl MA, Pahwa S. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. *PLoS One* 2013; 8:e79816; PMID:24236161; <https://doi.org/10.1371/journal.pone.0079816>
- [32] Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I. Advances in human B cell phenotypic profiling. *Front Immunol* 2012; 3:302; PMID:23087687; <https://doi.org/10.3389/fimmu.2012.00302>
- [33] Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ, Sanz I, Anolik JH. Novel human transitional B cell populations revealed by B cell depletion therapy. *J Immunol* 2009; 182:5982-93; PMID:19414749; <https://doi.org/10.4049/jimmunol.0801859>
- [34] Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, Nilsson BO, Wikby A, Kipling D, Dunn-Walters DK. B-cell diversity decreases in old age and is correlated with poor health status. *Aging Cell* 2009; 8:18-25; PMID:18986373; <https://doi.org/10.1111/j.1474-9726.2008.00443.x>
- [35] Frasca D, Landin AM, Lechner SC, Ryan JG, Schwartz R, Riley RL, Blomberg BB. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. *J Immunol* 2008; 180:5283-90; PMID:18390709; <https://doi.org/10.4049/jimmunol.180.8.5283>
- [36] Colonna-Romano G, Bulati M, Aquino A, Pellicano M, Vitello S, Lio D, Candore G, Caruso C. A double-negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. *Mech Ageing Dev* 2009; 130:681-90; PMID:19698733; <https://doi.org/10.1016/j.mad.2009.08.003>
- [37] Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, Kottlilil S, Arthos J, Proschan MA, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. *J Exp Med* 2008; 205:1797-805; PMID:18625747; <https://doi.org/10.1084/jem.20072683>
- [38] Chong Y, Ikematsu H, Yamamoto M, Murata M, Yamaji K, Nishimura M, Nabeshima S, Kashiwagi S, Hayashi J. Increased frequency of CD27- (naive) B cells and their phenotypic alteration in HIV type 1-infected patients. *AIDS Res Hum Retroviruses* 2004; 20:621-9; PMID:15242538; <https://doi.org/10.1089/0889222041217455>
- [39] De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. *AIDS* 2001; 15:957-64; PMID:11399977; <https://doi.org/10.1097/00002030-200105250-00003>
- [40] Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, Krishnan SR, Planta MA, Turney JF, Justement JS, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. *J Exp Med* 2004; 200:587-99; PMID:15508184; <https://doi.org/10.1084/jem.20032236>
- [41] Fogli M, Torti C, Malacarne F, Fiorentini S, Albani M, Izzo I, Giagulli C, Maggi F, Carosi G, Caruso A. Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naive for HAART is related to reduced immune surveillance. *Clin Dev Immunol* 2012; 2012:829584; PMID:22474482; <https://doi.org/10.1155/2012/829584>
- [42] Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, Liu S, Adelsberger J, Lapointe R, Hwu P, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. *Proc Natl Acad Sci U S A* 2001; 98:10362-7; PMID:11504927; <https://doi.org/10.1073/pnas.181347898>
- [43] Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, Cremers J, Hellings JA, Danner SA, de Ronde A. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. *AIDS Res*

- Hum Retroviruses 2001; 17:1003-8; PMID:11485617; <https://doi.org/10.1089/088922201300343681>
- [44] Shearer WT, Easley KA, Goldfarb J, Rosenblatt HM, Jenson HB, Kovacs A, McIntosh K. Prospective 5-year study of peripheral blood CD4, CD8, and CD19/CD20 lymphocytes and serum Igs in children born to HIV-1 women. The P(2)C(2) HIV Study Group. *J Allergy Clin Immunol* 2000; 106:559-66; PMID:10984378; <https://doi.org/10.1067/mai.2000.109433>
- [45] Blomberg BB, Frasca D. Age effects on mouse and human B cells. *Immunol Res* 2013; 57:354-60; PMID:24203437; <https://doi.org/10.1007/s12026-013-8440-9>
- [46] Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O'Shea MA, Roby G, Mican JM, Kottlil S, Chun TW, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. *J Infect Dis* 2008; 197:572-9; PMID:18240953; <https://doi.org/10.1086/526789>
- [47] Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, Hurley A, Cao Y, Markowitz M, Ho DD, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. *J Exp Med* 1998; 188:233-45; PMID:9670036; <https://doi.org/10.1084/jem.188.2.233>
- [48] Malaspina A, Moir S, Kottlil S, Hallahan CW, Ehler LA, Liu S, Planta MA, Chun TW, Fauci AS. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. *J Immunol* 2003; 170:5965-72; PMID:12794123; <https://doi.org/10.4049/jimmunol.170.12.5965>
- [49] Cagigi A, Nilsson A, De Milito A, Chiodi F. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. *Vaccine* 2008; 26:3016-25; PMID:18164520; <https://doi.org/10.1016/j.vaccine.2007.11.063>
- [50] De Milito A. B lymphocyte dysfunctions in HIV infection. *Curr HIV Res* 2004; 2:11-21; PMID:15053337; <https://doi.org/10.2174/1570162043485068>
- [51] Pensiero S, Galli L, Nozza S, Ruffin N, Castagna A, Tambussi G, Hejdeman B, Misciagna D, Riva A, Malnati M, et al. B-cell subset alterations and correlated factors in HIV-1 infection. *AIDS* 2013; 27:1209-17; PMID:23343911; <https://doi.org/10.1097/QAD.0b013e32835edc47>
- [52] Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, Streeck H, Johnston MN, Staller KD, Zaman MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. *Blood* 2005; 106:3366-9; PMID:16002429; <https://doi.org/10.1182/blood-2005-03-1100>
- [53] Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. *J Leukoc Biol* 2010; 88:1119-30; PMID:20651298; <https://doi.org/10.1189/jlb.0410225>
- [54] Naranbhai V, Altfeld M, Karim SS, Ndung'u T, Karim QA, Carr WH. Changes in Natural Killer cell activation and function during primary HIV-1 Infection. *PLoS One* 2013; 8:e53251; PMID:23326405; <https://doi.org/10.1371/journal.pone.0053251>
- [55] Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, O'Shea MA, Kinter A, Kovacs C, Moretta A, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. *Proc Natl Acad Sci U S A* 2005; 102:2886-91; PMID:15699323; <https://doi.org/10.1073/pnas.0409872102>
- [56] Le Garff-Tavernier M, Beziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debré P, Merle-Beral H, Vieillard V. Human NK cells display major phenotypic and functional changes over the life span. *Aging Cell* 2010; 9:527-35; PMID:20477761; <https://doi.org/10.1111/j.1474-9726.2010.00584.x>
- [57] Solana R, Campos C, Pera A, Tarazona R. Shaping of NK cell subsets by aging. *Curr Opin Immunol* 2014; 29:56-61; PMID:24792889; <https://doi.org/10.1016/j.coi.2014.04.002>
- [58] Bayard C, Lepetitcorps H, Roux A, Larsen M, Faste-nackels S, Salle V, Vieillard V, Marchant A, Stern M, Boddaert J, et al. Coordinated expansion of both memory T cells and NK cells in response to CMV infection in humans. *Eur J Immunol* 2016; 46:1168-79; PMID:26910859
- [59] Fauci AS, Mavilio D, Kottlil S. NK cells in HIV infection: paradigm for protection or targets for ambush. *Nat Rev Immunol* 2005; 5:835-43; PMID:16239902; <https://doi.org/10.1038/nri1711>
- [60] Mavilio D, Lombardo G, Kinter A, Fogli M, La Sala A, Ortolano S, Farschi A, Follmann D, Gregg R, Kovacs C, et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. *J Exp Med* 2006; 203:2339-50; PMID:17000867; <https://doi.org/10.1084/jem.20060894>
- [61] Martin MP, Carrington M. Natural killer cells and HIV-1 disease. *Curr Opin HIV AIDS* 2006; 1:226-31; PMID:19372814; <https://doi.org/10.1097/01.COHA.0000221597.79906.f6>
- [62] Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, Miller JS, Carrington M, Altfeld M. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. *J Virol* 2009; 83:6798-805; PMID:19386717; <https://doi.org/10.1128/JVI.00256-09>
- [63] Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, Retière C, Sverremark-Ekström E, Traherne J, Ljungman P, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. *Blood* 2013; 121:2678-88; PMID:23325834; <https://doi.org/10.1182/blood-2012-10-459545>
- [64] Boulet S, Kleyman M, Kim JY, Kanya P, Sharafi S, Simic N, Bruneau J, Routy JP, Tsoukas CM, Bernard NF. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. *AIDS* 2008; 22:1487-91; PMID:18614872; <https://doi.org/10.1097/QAD.0b013e3282ffde7e>
- [65] De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, Moretta A, Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). *Eur J Immunol* 2003; 33:2410-8; PMID:12938217; <https://doi.org/10.1002/eji.200324141>
- [66] Azzoni L, Papasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, Perussia B, Montaner LJ. Sustained impairment of IFN-gamma secretion in suppressed HIV-

- infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. *J Immunol* 2002; 168:5764-70; PMID:12023377; <https://doi.org/10.4049/jimmunol.168.11.5764>
- [67] Bozzano F, Nasi M, Bertonecelli L, Nemes E, Prati F, Marras F, Mussini C, Moretta L, Cossarizza A, De Maria A, et al. NK-cell phenotype at interruption underlies widely divergent duration of CD4⁺-guided antiretroviral treatment interruption. *Int Immunol* 2011; 23:109-18; PMID:21216830; <https://doi.org/10.1093/intimm/dxq462>
- [68] Leeansyah E, Zhou J, Paukovics G, Lewin SR, Crowe SM, Jaworowski A. Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study. *PLoS One* 2010; 5:e9643; PMID:20224795; <https://doi.org/10.1371/journal.pone.0009643>
- [69] Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, Kramski M, Hearps AC, Cameron PU, Lewin SR, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. *J Immunol* 2012; 189:1491-9; PMID:22745371; <https://doi.org/10.4049/jimmunol.1200458>
- [70] Crowe SM, Ziegler-Heitbrock L. Editorial: Monocyte subpopulations and lentiviral infection. *J Leukoc Biol* 2010; 87:541-3; PMID:20356904; <https://doi.org/10.1189/jlb.0909637>
- [71] Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. *PLoS One* 2008; 3:e2516; PMID:18575590; <https://doi.org/10.1371/journal.pone.0002516>
- [72] Hearps AC, Martin GE, Angelovich TA, Cheng WJ, Maisa A, Landay AL, Jaworowski A, Crowe SM. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. *Aging Cell* 2012; 11:867-75; PMID:22708967; <https://doi.org/10.1111/j.1474-9726.2012.00851.x>
- [73] Nyugen J, Agrawal S, Gollapudi S, Gupta S. Impaired functions of peripheral blood monocyte subpopulations in aged humans. *J Clin Immunol* 2010; 30:806-13; PMID:20703784; <https://doi.org/10.1007/s10875-010-9448-8>
- [74] Seidler S, Zimmermann HW, Bartneck M, Trautwein C, Tacke F. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. *BMC Immunol* 2010; 11:30; PMID:20565954; <https://doi.org/10.1186/1471-2172-11-30>
- [75] Jaworowski A, Ellery P, Maslin CL, Naim E, Heinlein AC, Ryan CE, Paukovics G, Hocking J, Sonza S, Crowe SM. Normal CD16 expression and phagocytosis of *Mycobacterium avium* complex by monocytes from a current cohort of HIV-1-infected patients. *J Infect Dis* 2006; 193:693-7; PMID:16453265; <https://doi.org/10.1086/500367>
- [76] Angelovich TA, Hearps AC, Maisa A, Martin GE, Lichtfuss GF, Cheng WJ, Palmer CS, Landay AL, Crowe SM, Jaworowski A. Viremic and virologically suppressed HIV infection increases age-related changes to monocyte activation equivalent to 12 and 4 years of aging, respectively. *J Acquir Immune Defic Syndr* 2015; 69:11-7; PMID:25647525; <https://doi.org/10.1097/QAI.0000000000000559>
- [77] Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, Landay AL, Jaworowski A, Crowe SM. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. *AIDS* 2012; 26:843-53; PMID:22313961; <https://doi.org/10.1097/QAD.0b013e328351f756>
- [78] Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. *Cell* 2001; 106:259-62; PMID:11509173; [https://doi.org/10.1016/S0092-8674\(01\)00456-1](https://doi.org/10.1016/S0092-8674(01)00456-1)
- [79] Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. *Hum Immunol* 2009; 70:777-84; PMID:19596035; <https://doi.org/10.1016/j.humimm.2009.07.005>
- [80] Panda A, Qian F, Mohanty S, van Duin D, Newman FK, Zhang L, Chen S, Towle V, Belshe RB, Fikrig E, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. *J Immunol* 2010; 184:2518-27; PMID:20100933; <https://doi.org/10.4049/jimmunol.0901022>
- [81] Shodell M, Siegal FP. Circulating, interferon-producing plasmacytoid dendritic cells decline during human ageing. *Scand J Immunol* 2002; 56:518-21; PMID:12410802; <https://doi.org/10.1046/j.1365-3083.2002.01148.x>
- [82] Chehimi J, Campbell DE, Azzoni L, Bacheller D, Pappasavas E, Jerandi G, Mounzer K, Kostman J, Trinchieri G, Montaner LJ. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. *J Immunol* 2002; 168:4796-801; PMID:11971031; <https://doi.org/10.4049/jimmunol.168.9.4796>
- [83] Grassi F, Hosmalin A, McIlroy D, Calvez V, Debre P, Autran B. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. *AIDS* 1999; 13:759-66; PMID:10357374; <https://doi.org/10.1097/00002030-199905070-00004>
- [84] Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L, Huang L, Levy JA, Liu YJ. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. *Blood* 2001; 98:906-12; PMID:11493432; <https://doi.org/10.1182/blood.V98.4.906>
- [85] Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, Meyer L, Oksenhendler E, Sinet M, Hosmalin A. Reduced blood CD123⁺ (lymphoid) and CD11c⁺ (myeloid) dendritic cell numbers in primary HIV-1 infection. *Blood* 2001; 98:3016-21; PMID:11698285; <https://doi.org/10.1182/blood.V98.10.3016>
- [86] Feldman S, Stein D, Amrute S, Denny T, Garcia Z, Kloser P, Sun Y, Megjugorac N, Fitzgerald-Bocarsly P. Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. *Clin Immunol* 2001; 101:201-10; PMID:11683579; <https://doi.org/10.1006/clim.2001.5111>

- [87] Benlahrech A, Yasmin A, Westrop SJ, Coleman A, Herasimtschuk A, Page E, Kelleher P, Gotch F, Imami N, Patterson S. Dysregulated immunophenotypic attributes of plasmacytoid but not myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy. *Clin Exp Immunol* 2012; 170:212-21; PMID:23039892; <https://doi.org/10.1111/j.1365-2249.2012.04647.x>
- [88] Kader M, Smith AP, Guiducci C, Wonderlich ER, Normolle D, Watkins SC, Barrat FJ, Barratt-Boyes SM. Blocking TLR7- and TLR9-mediated IFN-alpha production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection. *PLoS Pathog* 2013; 9:e1003530; PMID:23935491; <https://doi.org/10.1371/journal.ppat.1003530>
- [89] Li G, Cheng M, Nunoya J, Cheng L, Guo H, Yu H, Liu YJ, Su L, Zhang L. Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice. *PLoS Pathog* 2014; 10:e1004291; PMID:25077616; <https://doi.org/10.1371/journal.ppat.1004291>
- [90] Isgro A, Leti W, De Santis W, Marzali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. *Clin Infect Dis* 2008; 46:1902-10; PMID:18462177; <https://doi.org/10.1086/588480>
- [91] Jenkins M, Hanley MB, Moreno MB, Wieder E, McCune JM. Human immunodeficiency virus-1 infection interrupts thymopoiesis and multilineage hematopoiesis in vivo. *Blood* 1998; 91:2672-8; PMID:9531575
- [92] Marandin A, Katz A, Oksenhendler E, Tulliez M, Picard F, Vainchenker W, Louache F. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. *Blood* 1996; 88:4568-78; PMID:8977248
- [93] Moses A, Nelson J, Bagby GC, Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. *Blood* 1998; 91:1479-95; PMID:9473211
- [94] Clark DR, Ampel NM, Hallett CA, Yedavalli VR, Ahmad N, DeLuca D. Peripheral blood from human immunodeficiency virus type 1-infected patients displays diminished T cell generation capacity. *J Infect Dis* 1997; 176:649-54; PMID:9291311; <https://doi.org/10.1086/514086>
- [95] Clark DR, Repping S, Pakker NG, Prins JM, Notermans DW, Wit FW, Reiss P, Danner SA, Coutinho RA, Lange JM, et al. T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy. *Blood* 2000; 96:242-9; PMID:10891457
- [96] Kyoizumi S, Kubo Y, Kajimura J, Yoshida K, Imai K, Hayashi T, Nakachi K, Young LF, Moore MA, van den Brink MR, et al. Age-associated changes in the differentiation potentials of human circulating hematopoietic progenitors to T- or NK-lineage cells. *J Immunol* 2013; 190:6164-72; PMID:23670190; <https://doi.org/10.4049/jimmunol.1203189>
- [97] Guo X, He S, Lv X, Ding H, Li S, Kang J, Liu J, Qin C, Geng W, Jiang Y, Shang H. The Role of HIV-1 in Affecting the Proliferation Ability of HPCs Derived From BM. *J Acquir Immune Defic Syndr* 2016; 71:467-73; PMID:26974413; <https://doi.org/10.1097/QAI.0000000000000892>
- [98] Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, Savona MR, Collins KL. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. *Nat Med* 2010; 16:446-51; PMID:20208541; <https://doi.org/10.1038/nm.2109>
- [99] Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. *Science* 1988; 242:919-22; PMID:2460922; <https://doi.org/10.1126/science.2460922>
- [100] Neal TF, Holland HK, Baum CM, Villinger F, Ansari AA, Saral R, Wingard JR, Fleming WH. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. *Blood* 1995; 86:1749-56; PMID:7544640
- [101] Stanley SK, Kessler SW, Justement JS, Schnittman SM, Greenhouse JJ, Brown CC, Musongela L, Musey K, Kapita B, Fauci AS. CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. *J Immunol* 1992; 149:689-97; PMID:1378076
- [102] von Laer D, Hufert FT, Fenner TE, Schwander S, Dietrich M, Schmitz H, Kern P. CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. *Blood* 1990; 76:1281-6; PMID:1698476
- [103] Dorival C, Brizzi F, Lelievre JD, Sol-Foulon N, Six E, Henry A, André-Schmutz I, Cavazzana-Calvo M, Coulombel L, Estaquier J, et al. HIV-1 Nef protein expression in human CD34+ progenitors impairs the differentiation of an early T/NK cell precursor. *Virology* 2008; 377:207-15; PMID:18555888; <https://doi.org/10.1016/j.virol.2008.04.009>
- [104] Prost S, Le Dantec M, Auge S, Le Grand R, Derdouch S, Auregan G, Déglon N, Relouzat F, Aubertin AM, Maillere B, et al. [Nef and PPAR-gamma interact to suppress Stat5 expression in CD34+ progenitors from infected macaques]. *Med Sci (Paris)* 2008; 24:551-3; PMID:18466737; <https://doi.org/10.1051/medsci/2008245551>
- [105] Moses AV, Williams S, Heneveld ML, Strussenberg J, Rarick M, Loveless M, Bagby G, Nelson JA. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. *Blood* 1996; 87:919-25; PMID:8562963
- [106] Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006; 12:1365-71; PMID:17115046; <https://doi.org/10.1038/nm1511>
- [107] Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. *J Clin Invest* 2009; 119:3544-55; PMID:19959873